Previous 10 | Next 10 |
Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipeline Manufacturing to take place at Lonza’s GMP site in Geleen, Netherlands Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS), a cl...
Pixabay Data is the foundation of investing. Most investment focuses on data in the form of earnings per share, PE multiple, revenue growth, PEG ratio, etc. Biotech clinical results are based upon data. This article is a vehicle to present alternative data used to help understand clinical ...
Cellectis (NASDAQ: CLLS ): Q2 Non-GAAP EPS of -$0.65 misses by $0.29 ; GAAP EPS of -$0.79 misses by $0.19 . More news on: Cellectis S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
FDA approved IND for UCARTCS1 – first allogeneic CAR T-cell product candidate in multiple myeloma (MM) Ongoing construction of in-house manufacturing facilities: IMPACT in Raleigh, NC and SMART in Paris, France Published novel manufacturing methods to improve allogeneic...
SWIFF-CAR, a Next Generation CAR with an Embedded On/Off-Switch Increases Safety for Patients and Extends Manufacturing Possibilities Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190708005725/en/ ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 108 weeks of public selections as part of this ongoing live forward-testing. In...
Regulatory News: Cellectis S.A. held its Combined Shareholders Meeting (Euronext Growth: ALCLS; Nasdaq: CLLS) on June 25, 2019 at its head office in Paris. At the meeting, during which more than 68% of voting rights were exercised, Resolutions 1 through 18, 23 and 24 were adopted. R...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
The following slide deck was published by Cellectis S.A. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...